Status:
COMPLETED
Tolerance and Acute Effects of a New HFNT Nasal Cannula
Lead Sponsor:
Temple University
Collaborating Sponsors:
Fisher and Paykel Healthcare
Conditions:
COPD Exacerbation Acute
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
In the care of patients experiencing an acute exacerbation of COPD, supplemental oxygen therapy is often required. Oxygen is typically administered at flow rates between 1 and 4 liters per minute. Hig...
Detailed Description
AIRVO 2: The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. Th...
Eligibility Criteria
Inclusion
- i.aged ≥ 40 years (ii) hospitalization for acute exacerbation of COPD; (iii) smoker or ex-smoker (iv) FEV1 \<80% of predicted and FEV1/FVC \<70% postbronchodilator within 12 months prior to admission (v) have no other lung disease (including asthma) as a principal cause of pulmonary function limitation (vi) baseline PaCO2 ≥ 45 mm Hg at study entry. (vii) willing to give informed consent (viii) willing to participate in measurement of ABGs (ix) will to provide a brief history and physical examination and answer questionnaires.
Exclusion
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Women who are known to be pregnant at the time of hospital admission
- Prisoners
- Individuals who do not understand English
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05182294
Start Date
May 25 2022
End Date
January 31 2023
Last Update
April 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140